Diagnostic Lung Investigations for Cough with Mold Exposure
For a patient with cough and suspected mold exposure, obtain a thin-section chest CT (1.25-1.5 mm), serum total IgE, peripheral blood eosinophil count, and sputum fungal culture as your initial diagnostic workup. 1
Clinical Context Determines the Diagnostic Pathway
The specific lung investigations depend critically on whether you suspect allergic bronchopulmonary aspergillosis/mycoses (ABPA/ABPM) versus hypersensitivity pneumonitis (HP). Both conditions present with cough and mold exposure but require different diagnostic approaches.
For Suspected ABPA/ABPM (typically in asthmatics):
Laboratory Testing:
- Serum total IgE ≥500 IU/mL (diagnostic cutoff) 1
- Peripheral blood eosinophil count ≥500 cells/μL 1
- Aspergillus fumigatus-specific IgG using population-specific cutoffs when available 1
- Sputum fungal culture to identify species and guide therapy (strongly recommended for ABPM, suggested for ABPA) 1
Imaging:
- Thin-section chest CT (1.25-1.5 mm slices) is critical for baseline diagnosis 1
- Look specifically for: bronchiectasis, mucus plugging, and high-attenuation mucus (HAM)
- HAM appears denser than paraspinal muscles on non-contrast CT and is pathognomonic (35% sensitivity, 100% specificity) 1
- Use chest radiograph for follow-up, not repeat CT 1
What NOT to do:
- Do NOT use serum galactomannan for ABPA diagnosis 1
- Do NOT routinely perform bronchoscopy unless: uncertain diagnosis, sputum cultures uninformative in suspected ABPM, unexplained hemoptysis, or suspected chronic infection before starting steroids 1
For Suspected Hypersensitivity Pneumonitis:
Imaging:
- High-resolution chest CT showing characteristic findings: profuse centrilobular ground-glass nodules, inspiratory mosaic attenuation with air-trapping, and the three-density sign 2
- Integrate CT findings with clinical context; do not use CT alone for definitive diagnosis 2
Laboratory Testing:
- Mold-specific IgG testing can be performed but has significant limitations 2, 3
- Suggested cutoffs (mgA/L): Aspergillus fumigatus 33, Penicillium chrysogenum 22, Cladosporium herbarum 34, Micropolyspora faeni 8 3
- A positive 4-mold panel (any sIgG exceeding cutoff) shows 57.1% sensitivity and 78.1% specificity 3
- Critical caveat: Do NOT rely solely on serum IgG/IgA testing to confirm or rule out HP due to lack of standardization and variable cutoffs 2
What NOT to do:
- Do NOT perform antigen-specific inhalation challenge testing (not standardized or validated) 2
- Do NOT perform antigen-specific lymphocyte proliferation testing (lacks standardization) 2
- Do NOT rely solely on clinical improvement with antigen avoidance or medical therapy to confirm/exclude HP 2
Common Pitfalls to Avoid
Do not measure indoor mold levels for medical diagnostic purposes—this is generally not indicated and does not guide clinical management 4, 5
Do not test blood or urine for mold components or metabolites—these lack diagnostic utility 4, 5
Recognize immunocompromised patients require immediate action: If your patient has grade 2-3 immunosuppression, severe influenza, severe COVID-19, cystic fibrosis, or uncontrolled asthma, immediately eliminate mold exposure before completing diagnostic workup 5
Consider environmental inspection: When exposure history is unclear despite detailed questioning, physical inspection of the patient's dwelling may reveal the mold source (look for condensation-soaked areas, visible mold on walls/tapestries, especially near windows and in bedrooms) 6
Algorithmic Approach
- History: Document asthma history, immunosuppression status, specific exposure details
- Initial labs: Total IgE, eosinophil count, sputum culture
- Imaging: Thin-section chest CT (1.25-1.5 mm)
- If asthmatic with elevated IgE/eosinophils: Add Aspergillus-specific IgG → suspect ABPA/ABPM
- If non-asthmatic with characteristic CT findings: Consider HP, may add mold-specific IgG panel (understanding limitations)
- Reserve bronchoscopy for uncertain diagnoses or when sputum cannot be obtained